Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis
Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis - read this article along with other careers information, tips and advice on BioSpace
Corey Davis Ocuphire Pharma Iuvo Bioscience Mina Sooch Nyxol Development Plan Oculos Development Services
Source: biospace.com